Clinical Trial

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess the safety and efficacy of tenapanor (5 mg, 25mg, and 50 mg) in adult patients with Chronic Idiopathic Constipation (CIC) when administered twice daily for 26 consecutive weeks.
Protocol Amendment History 1 change
notable Trial sites expanded: 79 -> 109 locations 2026-06-05
Trial Details
NCT Number NCT07382167
Lead Sponsor Ardelyx
Conditions Chronic Idiopathic Constipation (CIC)
Enrollment 692 participants
Start Date 2026-01-13
Primary Completion 2027-02-26 (estimated)
Study Completion 2027-06-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-04